Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00012298 · ClinicalTrials.gov registry record · Phase 1
Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- Phase 1
- Development phase
- 81
- Enrollment target
NCT00012298: Clinical Trial Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00012298 is a Phase 1 study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 81 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00012298, a Phase 1 study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 81 participants
- Enrollment target
Study Summary
Phase I/II trial to study the effectiveness of combining radiolabeled monoclonal antibody therapy and rituximab with and without filgrastim and interleukin-11 in treating patients who have relapsed or refractory non-Hodgkin's lymphoma. Radiolabeled monoclonal antibodies can locate cancer cells and deliver cancer-killing substances to them without harming normal cells. Biological therapies such as filgrastim and interleukin-11 use different ways to stimulate the immune system and stop cancer cells from growing.
Interventions
- BIOLOGICAL rituximab
- BIOLOGICAL filgrastim
- BIOLOGICAL yttrium Y 90 ibritumomab tiuxetan
- BIOLOGICAL indium In 111 ibritumomab tiuxetan
- BIOLOGICAL oprelvekin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2001-04 |
| Est. Completion | 2010-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00012298
The ClinicalTrials.gov registry entry for NCT00012298 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 81 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which rituximab is the first listed.
NCT00012298 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00012298 about?
NCT00012298 is a clinical study titled "Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma". Phase I/II trial to study the effectiveness of combining radiolabeled monoclonal antibody therapy and rituximab with and without filgrastim and interleukin-11 in treating patients who have relapsed or refractory non-Hodgkin's lymphoma. Radiolabeled monoclonal antibodies can locate cancer cells and d...
What is the current status of trial NCT00012298?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 81 participants. The study started on 2001-04. Estimated completion is 2010-04.
What interventions are being tested in trial NCT00012298?
The interventions under investigation include: rituximab (BIOLOGICAL), filgrastim (BIOLOGICAL), yttrium Y 90 ibritumomab tiuxetan (BIOLOGICAL), indium In 111 ibritumomab tiuxetan (BIOLOGICAL), oprelvekin (BIOLOGICAL).
Who is sponsoring clinical trial NCT00012298?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.